The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 21, 2017

Filed:

Jan. 25, 2016
Applicant:

Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Pamela Tan, Kulmbach, DE;

Birgit Bramlage, Kulmbach, DE;

Maria Frank-Kamenetsky, Brookline, MA (US);

Kevin Fitzgerald, Brookline, MA (US);

Akin Akinc, Needham, MA (US);

Victor E. Kotelianski, Boston, MA (US);

Assignee:

Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/11 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/713 (2013.01); C12N 2310/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/332 (2013.01); C12N 2310/3515 (2013.01);
Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.


Find Patent Forward Citations

Loading…